摘要
目的:探讨德谷门冬双胰岛素治疗2型糖尿病(T2DM)的疗效及对糖化血红蛋白(HbA1c)控制率的影响。方法:选择2020年4月—2021年4月140例T2DM患者,随机分为研究组和对照组,各70例。研究组使用德谷门冬双胰岛素治疗,对照组使用甘精胰岛素治疗,比较两组治疗前后血糖、血脂及不良事件。结果:研究组24 h最高血糖、24h平均血糖、24 h血糖波动幅度优于对照组(P<0.05),而两组FPG、2hPG比较,差异无统计学意义(P>0.05);研究组HbA1c达标率高于对照组(P<0.05),而两组HbA1c水平、HOMA-β比较,差异无统计学意义(P>0.05);两组治疗前后血脂水平比较,差异无统计学意义(P>0.05);两组低血糖发生次数比较,差异无统计学意义(P>0.05),但研究组夜间低血糖发生次数少于对照组(P<0.05)。两组糖尿病急性并发症比较,差异无统计学意义(P>0.05)。结论:德谷门冬双胰岛素治疗T2DM具有确切优势,可有效提高HbA1c达标率。
Objective:To investigate the efficacy of insulin degludec/insulin aspart in the treatment of type 2 diabetes mellitus(T2DM)and its influence on the control rate of glycosylated hemoglobin(HbA1c).Methods:A total of 140 T2DM patients from April 2020 to April 2021 were selected and randomly divided into the study group and the control group,with 70 cases in each.The study group was treated with insulin degludec/insulin aspart,and the control group was treated with insulin glargine.The blood glucose,blood lipids and adverse events were compared between the two groups before and after treatment.Results:The 24 h highest blood sugar,24 h average blood sugar,and 24h blood sugar fluctuation range in the study group were better than those in the control group(P<0.05),but there was no significant difference in FPG and 2hPG between the two groups(P>0.05).The HbA1c compliance rate in the study group was higher than that in the control group(P<0.05),but there was no significant difference in HbA1c levels and HOMA-βbetween the two groups(P>0.05).There was no significant difference in blood lipid levels between the two groups before and after treatment(P>0.05);there was no significant difference in the frequency of hypoglycemia between the two groups(P>0.05),but the frequency of nocturnal hypoglycemia in the study group was less than that in the control group(P<0.05).There was no significant difference in acute complications of diabetes between the two groups(P>0.05).Conclusion:Insulin degludec/insulin aspart has definite advantages in the treatment of T2DM and can effectively improve the standard rate of HbA1c.
作者
李学彬
王雪梅
LI Xuebin;WANG Xuemei(Department of Endocrinology and Nephrology,Ninghe District Hospital,Tianjin,301509)
出处
《中国药物滥用防治杂志》
CAS
2022年第9期1287-1291,共5页
Chinese Journal of Drug Abuse Prevention and Treatment
关键词
德谷门冬双胰岛素
2型糖尿病
糖化血红蛋白
Insulin degludec/insulin aspart
Type 2 diabetes mellitus
Glycosylated hemoglobin
